drug
EXEMESTANE
Marketedupdated 5mo agoby $PFE PFIZER INC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2indications
investigational
Breast Cancer
all catalysts(8)
approval · 8
Apr 1, 2011
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Aug 3, 2011
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Jul 6, 2015
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Jul 6, 2015
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Aug 13, 2020
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Aug 13, 2020
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Jun 15, 2022
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Oct 7, 2025
approval
EXEMESTANE — FDA approval
EXEMESTANE
→
Trials studying EXEMESTANE
- phase3A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- phase3Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- phase1A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- phase3Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
- phase2A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
- phase3A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- phase3OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- phase3An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that